(Q35578064)

English

Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?

scientific article published on November 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us? (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

10.1016/S0889-857X(03)00059-0

https://api.crossref.org/works/10.1016/S0889-857X(03)00059-0

29 March 2024

author name string

Jaime A. Oviedo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603582

29 March 2024

M. Michael Wolfe

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603582

29 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14603582

29 March 2024

publication date

1 November 2003

1 reference

Europe PubMed Central

9 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0889857X03000590?httpAccept=text/xml

1 reference

10.1016/S0889-857X(03)00059-0

https://api.crossref.org/works/10.1016/S0889-857X(03)00059-0

29 March 2024

https://api.elsevier.com/content/article/PII:S0889857X03000590?httpAccept=text/plain

1 reference

10.1016/S0889-857X(03)00059-0

https://api.crossref.org/works/10.1016/S0889-857X(03)00059-0

29 March 2024

Rheumatic Diseases Clinics of North America

1 reference

Europe PubMed Central

9 August 2017

29

1 reference

Europe PubMed Central

9 August 2017

4

1 reference

Europe PubMed Central

9 August 2017

769-788

1 reference

Europe PubMed Central

9 August 2017

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical potential of cyclo-oxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between naproxen use and protection against acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Omeprazole ameliorates aspirin-induced gastroduodenal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900059-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use

2

1 reference

10.1016/S0889-857X(03)00059-0

https://api.crossref.org/works/10.1016/S0889-857X(03)00059-0

29 March 2024

COX-1 and COX-2 tissue expression: implications and predictions

15

1 reference

10.1016/S0889-857X(03)00059-0

https://api.crossref.org/works/10.1016/S0889-857X(03)00059-0

29 March 2024

Identifiers

10.1016/S0889-857X(03)00059-0

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35578064&oldid=2113900158"